We were surprised to read a Dow Jones story last week reporting that GlaxoSmithKline had "refused" to sell some of its medicines to a generic manufacturer. We were surprised because, in fact, we have offered in writing to sell the medicines and have outlined the steps necessary--primarily confirmation that FDA would allow the sale and approve the generic company's planned research.
"After FDA has considered the issues...GSK would be pleased to work with (the generic company) consistent with FDA's conditions to address GSK's business and liability concerns," conclude the GSK letters, which the reporter had obtained. The generic company has not responded to GSK.
The Merriam-Webster Dictionary defines "refuse" as "show or express unwillingness to do." The characterization does not fit this situation and the Dow Jones story did not accurately report our position.
We wanted to share these facts and set the record straight.
Leave a comment